Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

Nicolas Williet,Angelique Saint,Anne-Laure Pointet,David Tougeron,Simon Pernot,Astrid Pozet,Dominique Bechade,Isabelle Trouilloud,Nelson Lourenço,Vincent Hautefeuille,Christophe Locher,Jérôme Desramé,Pascal Artru,Anne Thirot-Bidault,Bertrand Le Roy,Denis Pezet,Jean-Marc Phelip,Julien Taieb

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

2019

Nicolas Williet
Angelique Saint
Anne-Laure Pointet
David Tougeron
Simon Pernot
Astrid Pozet
Dominique Bechade
Isabelle Trouilloud
Nelson Lourenço
Vincent Hautefeuille
Christophe Locher
Jérôme Desramé
Pascal Artru
Anne Thirot-Bidault
Bertrand Le Roy
Denis Pezet
Jean-Marc Phelip
Julien Taieb

Background:Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemot...

Keywords:

Propensity score matching
Diabetes mellitus
Metastatic pancreatic cancer
Oncology
Pathology
Gemcitabine
FOLFIRINOX
Medicine
Nab-paclitaxel
Internal medicine
in patient
first line therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations